Zymeworks Reports the First Patient Dosing with ZW191 in P-I Study for Treating Folate Receptor-⍺ Expressing Advanced Solid Tumors
Shots:
- Zymeworks has dosed the first patient with ZW191 under P-I clinical evaluation for treating FR⍺-expressing solid tumors such as ovarian, endometrial & NSCLC cancers
- The P-I trial will recruit 145 adults with advanced FR⍺-expressing cancers across North America, EU & Asia-Pacific, with part 1 assessing the safety, tolerability & dose escalation of ZW191 in ovarian, endometrial & NSCLC cancers (2EPs will be PK & confirmed ORR), while part 2 further evaluating safety & anti-tumor activity
- ZW191 is an ADC designed to target FR⍺ on above mentioned cancers. It internalizes into FR⍺-expressing cells to release Zymeworks' novel payload, ZD06519, a topoisomerase-1 inhibitor aimed at killing tumor cells
Ref: Zymeworks | Image: Zymeworks
Related News:- Zymeworks Reports the US FDA’s IND Clearance of ZW191 for Treating Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
